Autolus Therapeutics plc (AUTL) is a UK-based, commercial-stage biopharmaceutical company developing programmed T-cell (CAR-T) therapies for cancer and autoimmune diseases. Roughly nine current sell-side price targets were reviewed for this analysis, spanning approximately $5 to $11. The arithmetic mean is about $8.73, which rounds to a central target of $8.75.
The targets cluster in two groups. Needham, H.C. Wainwright, and Mizuho all publish $10 targets, while Goldman Sachs carries a $5.80 target (raised from $5.40 in August 2026) and Wells Fargo holds the low end at $5. William Blair reiterates a Buy rating but does not publish a dollar target. Needham, which named AUTL a top pick for 2026, argues the shares are attractively valued and models breakeven by 2028 on AUCATZYL sales alone. The cautious end of the range reflects skepticism about whether commercialization can outpace heavy spending. This wide dispersion is not unusual for an early-stage commercial biotech, but it means the "average analyst price target" should be read as a midpoint of divergent scenarios rather than a precise forecast.
Shares closed near $1.55 in late October 2026, toward the lower portion of a 52-week range of roughly $1.18 to $2.58. The company carries a market capitalization of approximately $413 million with trailing 12-month revenue of about $117 million and a net loss of roughly $280 million. Because the stock has no meaningful earnings, it trades on revenue multiples and pipeline expectations rather than a price-to-earnings ratio.
From $1.55, the move to $8.75 represents upside of approximately 465%, which must be characterized as very large. A path to that level would likely require several things to go right at once: continued acceleration of AUCATZYL revenue, successful early data readouts in lupus nephritis and multiple sclerosis, and a credible timeline to breakeven that persuades investors the company will not need heavily dilutive financing.
Autolus has meaningfully improved its commercial trajectory. AUCATZYL generated $45.7 million in net product revenue in the second quarter of 2026, up from $20.9 million a year earlier, and management raised full-year 2026 guidance to $140–150 million from $120–135 million. The company also secured a credit facility of up to $250 million with Perceptive Advisors, with $75 million funded at close, and expects its cash to fund operations into the fourth quarter of 2027.
Beyond the approved indication, the pipeline is the main source of upside. Obe-cel is being studied in lupus nephritis, progressive multiple sclerosis, light-chain amyloidosis, and pediatric B-ALL, and the FDA granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel. Analysts modeling the stock's potential value creation point to these optionalities, which receive little credit at the current share price.
The obstacles are substantial. The company remains deeply unprofitable, with a trailing net loss of roughly $280 million and negative earnings per share of about $1.05. Even with narrowing losses forecast for 2026, the business is expected to stay loss-making for the next several years. A 13% workforce reduction announced in 2026 underscores the pressure to control costs.
Competition in CD19-directed CAR-T and broader cell therapy is intense, and institutional ownership declined in recent quarters. The stock also trades below its book value, a sign the market is not yet convinced the commercial business can generate durable returns. Any clinical setback, slower-than-expected treatment-center uptake, or additional share issuance to raise capital could keep the shares depressed and the target well out of reach.
Technically, the shares sit well below all analyst price targets, with meaningful resistance near the $2.00 round level and the 52-week high around $2.58. Support is visible near $1.50 and again at the 52-week low around $1.18. A sustained move above $2.58 would represent a breakout from a prolonged downtrend and is a prerequisite for any credible advance toward the $5 to $10 levels implied by the analyst range.
Analyst price targets for AUTL generally reflect a roughly 12-month research horizon, though the spread between a $5 and an $11 target shows analysts disagree sharply on how quickly value will emerge. The next key event is the third-quarter earnings report scheduled for November 10, 2026, which will update AUCATZYL revenue momentum and cash position. Investors should also watch initial data from the progressive MS and amyloidosis programs expected by year-end 2026, any guidance revisions, and analyst target changes following earnings.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders spot opportunities, track existing positions, and identify shifting trends more efficiently than manual screening. For a volatile, event-driven name like Autolus, where clinical catalysts can move the stock sharply, such tools can complement fundamental research by surfacing real-time changes in momentum.
The $8.75 central target, derived from the average of roughly nine analyst price targets spanning about $5 to $11, implies a gain of approximately 465% from the current price near $1.55 — a very large move that would require flawless commercial execution and positive clinical data across multiple programs. The bull case rests on accelerating AUCATZYL sales and a pipeline that analysts argue is undervalued, while the bear case centers on sustained losses, a constrained cash runway, and fierce competition. With every covering firm maintaining a Buy rating but targets diverging dramatically, the target represents an aspirational scenario rather than a base case, and no outcome should be treated as assured.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To AUTL | 1D Price Change % | ||
|---|---|---|---|---|
| AUTL | 100% | -0.65% | ||
| CRSP - AUTL | 47% Loosely correlated | -0.77% | ||
| LXEO - AUTL | 43% Loosely correlated | -3.57% | ||
| RCKT - AUTL | 42% Loosely correlated | -0.44% | ||
| VIR - AUTL | 42% Loosely correlated | +4.45% | ||
| TSHA - AUTL | 41% Loosely correlated | +1.26% | ||
More | ||||